To Top
Close

Investment Advisory Services

Investment Advisory Services

Unlocking Strategic Growth in Healthcare & Life Sciences

At AKT Health, we provide data-driven investment advisory services designed to support investors, biotech firms, and healthcare companies in navigating complex transactions. Whether you’re seeking to acquire, invest in, or exit a healthcare asset, our proprietary intelligence platform and expert advisory team ensure successful deal execution with minimized risk and maximized value.

Buy-Side Advisory

For Investors, Private Equity, and Corporate Acquirers

  • M&A Target Identification & Due Diligence

    • Leverage AI-powered analytics to identify high-potential biotech, MedTech, and pharma assets.
    • Conduct deep due diligence, assessing clinical pipeline strength, regulatory pathways, and market viability.

  • Valuation & Financial Modeling

    • Provide risk-adjusted valuation models to guide investment decisions.
    • Structure optimal deal terms with NPV, IRR, and milestone-based financial analysis.

  • Regulatory & Market Access Strategy

    • Navigate FDA, EMA, PMDA, and global regulatory frameworks for seamless integration.
    • Assess reimbursement strategies and commercialization feasibility.

  • Post-Merger Integration & Value Maximization

    • Develop structured integration roadmaps to optimize synergies post-acquisition.
    • Ensure smooth operational and scientific alignment between entities.

  • Who We Support:

    • Private Equity & Venture Capital Firms
    • Corporate M&A & Strategy Teams (Pharma, Biotech, MedTech)
    • Investment Banks & Institutional Investors

Sell-Side Advisory

For Biotech Startups, Mid-Sized Firms & Healthcare Companies Seeking Investors or Acquirers

  • Strategic Positioning & Market Readiness

    • Optimize your company’s narrative, financials, and pipeline for investor interest.
    • Benchmark licensing and M&A deals to maximize valuation.

  • Investor & Partner Targeting

    • Identify global strategic buyers, pharma companies, and private equity investors.
    • Match with ideal licensing or acquisition partners in Japan, US, EU, and emerging markets.

  • Licensing & M&A Deal Structuring

    • Structure term sheets, royalty models, and milestone agreements for out-licensing.
    • Assist in negotiating financial and strategic terms with investors and acquirers.

  • Transaction Execution & Closing Support

    • Provide end-to-end transaction management, from due diligence to deal closure.
    • Oversee post-deal transition planning and integration.

  • Who We Support:

    • Biotech Startups & Mid-Stage Firms
    • University Spin-Offs & Research Institutions
    • Growth-Stage Healthcare & Life Sciences Companies

Why Choose AKT Health?

Proprietary Data & AI-Driven Insights

Access exclusive market intelligence for strategic decision-making.

Global Network of Investors & Buyers

Direct connections with top-tier PE firms, pharma leaders, and acquirers.

Regulatory & Financial Expertise

End-to-end support from valuation to deal closure.

Tailored M&A & Licensing Solutions

Custom strategies that align with your business objectives.

Case Studies: Proven Success in Healthcare & Life Sciences Investment Advisory

At AKT Health, we help investors, biotech firms, and healthcare companies navigate complex transactions with precision and strategic foresight. Here are real-world examples of how we’ve driven successful buy-side acquisitions and sell-side exits for our clients.

Buy-Side Case Studies

Case Study 1: Japanese Pharma Giant Acquires a U.S. Biotech Firm for Rare Disease Pipeline

  • Client

    A leading Japanese pharmaceutical company

  • Objective

    Expand into rare disease therapeutics through a strategic acquisition

  • Challenge

    Identifying the right U.S. biotech with a strong but undervalued clinical-stage asset

AKT Health’s Role:

Target Identification & Due Diligence

Used AI-powered scouting to identify biotech firms with promising rare disease assets.

Valuation & Risk Assessment

Conducted financial modeling & risk-adjusted projections to validate investment potential.

Regulatory & Market Entry Strategy

Assessed FDA and PMDA regulatory pathways for smooth approval post-acquisition.

Outcome:

$450M acquisition deal finalized, enabling the Japanese pharma company to enter the U.S. rare disease market with a high-growth pipeline.

Case Study 2: Private Equity Firm Acquires European MedTech Startup to Expand Digital Health Portfolio

  • Client

    A healthcare-focused private equity firm

  • Objective

    Acquire a fast-growing MedTech startup with AI-driven diagnostics

  • Challenge

    Identifying a scalable technology with regulatory approval potential

AKT Health’s Role:

Competitive Market Benchmarking

Analyzed comparable deals and identified undervalued AI-driven MedTech firms.

Regulatory & IP Due Diligence

Verified CE-marking, FDA approval roadmap, and IP security.

Post-Merger Integration Strategy

Developed an operational roadmap for seamless acquisition and scaling.

Outcome:

$200M acquisition completed, with the MedTech startup integrated into the PE firm’s digital health portfolio and successfully launched in new markets.

Sell-Side Case Studies

Case Study 3: Biotech Startup Secures $100M Licensing Deal with a Global Pharma Company

  • Client

    Early-stage biotech firm with a novel oncology therapy

  • Objective

    Out-license its lead asset to a global pharma partner

  • Challenge

    Finding the right strategic partner willing to invest in an early-stage asset

AKT Health’s Role:

Investor & Partner Targeting

Connected the biotech firm with global pharma players actively seeking oncology assets.

Valuation & Deal Structuring

Benchmarked similar licensing deals and structured royalties, milestones, and upfront payments.

Negotiation Support

Assisted in negotiating a favorable term sheet ensuring long-term value retention.

Outcome:

$100M licensing agreement secured, with the biotech firm retaining royalties and milestone-based payments. The deal accelerated the clinical development of their oncology asset.

Case Study 4: University Spin-Off Biotech Raises $50M Series B from Strategic Investors

  • Client

    A university-affiliated biotech company specializing in gene therapy

  • Objective

    Secure Series B funding from strategic investors and pharma partners

  • Challenge

    Convincing investors of the long-term commercial potential of an early-stage pipeline

AKT Health’s Role:

Strategic Positioning & Market Readiness

Refined the biotech’s investment pitch and developed a compelling commercialization roadmap.

Investor Targeting & Outreach

Engaged with strategic pharma investors and venture capital firms in Japan, U.S., and Europe.

Regulatory & Reimbursement Strategy

Provided insights into regulatory approval pathways and reimbursement strategies.

Outcome:

$50M Series B secured, enabling the biotech firm to advance its pipeline into Phase 2 clinical trials with a strong partner network.

Stay Relevant with

Decentralized Clinical Trails

The Future of Clinical Development in a Disruptive World.